StreetInsider.com News Articles

Datasea Inc. (DTSS) files $150M mixed shelf

Thu, 13 Aug 2026 16:44:06 -0400

Datasea Inc. (NASDAQ: DTSS) filed $150,000,000 mixed shelf of:
Class A Ordinary Shares, Debt Securities, Warrants, Units, and Rights

Datasea Inc. (DTSS) files $150M mixed shelf

Thu, 13 Aug 2026 16:44:06 -0400

Datasea Inc. (NASDAQ: DTSS) filed $150,000,000 mixed shelf of:
Class A Ordinary Shares, Debt Securities, Warrants, Units, and Rights

Datasea unit completes FDA registration for NeuroVibe biofeedback device

Tue, 11 Aug 2026 09:01:52 -0400

Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) announced that its China-based variable interest entity, Shuhai Jingwei (Shenzhen) Information Technology Co., has completed establishment registration and device listing with the U.S. Food and Drug Administration for its NeuroVibe Biofeedback System, covering products NV-02 and NV-03.

The devices are listed under FDA product code HCC as Class II 510(k)-exempt biofeedback medical devices within the neurology regulatory area. The company noted that FDA establishment registration and device listing do not constitute FDA approval, clearance, or authorization of the establishment or the listed devices.

NeuroVibe is described as a non-invasive biofeedback platform combining four technology components: acoustic

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Tue, 11 Aug 2026 09:01:00 -0400

BEIJING, Aug. 11, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digital solutions, today announced that Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd. ("Shuhai Jingwei"), the Company's variable interest entity in China, has completed establishment registration and device listing with the U.S. Food and Drug Administration ("FDA") for its NeuroVibe Biofeedback System, including products NV-02 and NV-03. The products are listed under FDA product

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Tue, 11 Aug 2026 09:01:00 -0400

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Tue, 11 Aug 2026 09:01:00 -0400

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Tue, 11 Aug 2026 09:01:00 -0400

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Tue, 11 Aug 2026 09:01:00 -0400

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Tue, 11 Aug 2026 09:01:00 -0400

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Tue, 11 Aug 2026 09:01:00 -0400

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Tue, 11 Aug 2026 09:01:00 -0400

Datasea Intelligent Technology Ltd. Announces CEO's Intention to Purchase Up to US$1.0 Million of the Company's Class A Ordinary Shares

Tue, 16 Jun 2026 09:30:00 -0400

BEIJING, June 16, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (Nasdaq: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digital solutions, today announced that Ms. Zhixin Liu, the Company's Chief Executive Officer and a beneficial owner of approximately 32% of the Company's outstanding shares, representing approximately 49% of the votes, has adopted a Rule 10b5-1 trading plan (the "Trading Plan") under which she intends to purchase up to US$1.0 million of the Company's Class A ordinary shares in open-market transactions.

Datasea Intelligent Technology Ltd. Announces CEO's Intention to Purchase Up to US$1.0 Million of the Company's Class A Ordinary Shares

Tue, 16 Jun 2026 09:30:00 -0400

Datasea Intelligent Technology Ltd. Announces CEO's Intention to Purchase Up to US$1.0 Million of the Company's Class A Ordinary Shares

Tue, 16 Jun 2026 09:30:00 -0400

Datasea Intelligent Technology Ltd. Announces CEO's Intention to Purchase Up to US$1.0 Million of the Company's Class A Ordinary Shares

Tue, 16 Jun 2026 09:30:00 -0400

Datasea Intelligent Technology Ltd. Announces Advancement of Compliance Work and Related Procedures for U.S. FDA Establishment Registration and Device Listing for Its Acoustic Brain-Computer Interface